Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene
- PMID: 1317259
Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene
Abstract
Amsacrine and demethylepipodophyllotoxins (etoposide and teniposide) are potent topoisomerase II inhibitors which have optimum activity in different cancers. To investigate whether these differences are due to different activity on cellular oncogenes, drug-induced topoisomerase II cleavage sites were mapped and sequenced in the human c-myc protooncogene. In the presence of purified murine L1210 topoisomerase II, amsacrine induces prominent cleavage in the P2 promoter (site 2499/2502). Footprinting experiments indicate that topoisomerase II binds to the entire promoter region (approximately 20 base pairs on the sides of the P2 site). In the case of teniposide or etoposide, cleavage is more diffuse and markedly less at the P2 site. Mapping of cleavage sites in human small cell lung carcinoma cells (NCI N417) also shows that cleavage in the P2 promoter region is induced preferentially by amsacrine but not by demethylepipodophyllotoxins. Thus, selective gene damage among topoisomerase II inhibitors may contribute to differential anticancer activity.
Similar articles
-
Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.Mol Pharmacol. 1995 Aug;48(2):238-49. Mol Pharmacol. 1995. PMID: 7651357
-
In vivo and in vitro stimulation by antitumor drugs of the topoisomerase II-induced cleavage sites in c-myc proto-oncogene.NCI Monogr. 1987;(4):41-7. NCI Monogr. 1987. PMID: 2819730
-
Drug-specific sites of topoisomerase II DNA cleavage in Drosophila chromatin: heterogeneous localization and reversibility.Cancer Res. 1996 Apr 15;56(8):1855-62. Cancer Res. 1996. PMID: 8620504
-
Mechanisms of resistance to drugs that inhibit DNA topoisomerases.Semin Cancer Biol. 1991 Aug;2(4):235-44. Semin Cancer Biol. 1991. PMID: 1655118 Review.
-
Does bulk damage to DNA explain the cytostatic and cytotoxic effects of topoisomerase II inhibitors?Biochem Pharmacol. 1991 Nov 27;42(12):2253-8. doi: 10.1016/0006-2952(91)90227-v. Biochem Pharmacol. 1991. PMID: 1662508 Review. No abstract available.
Cited by
-
TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas.Clin Cancer Res. 2021 Oct 15;27(20):5669-5680. doi: 10.1158/1078-0432.CCR-21-0312. Epub 2021 Aug 25. Clin Cancer Res. 2021. PMID: 34433651 Free PMC article.
-
DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors.Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5719-23. doi: 10.1073/pnas.92.12.5719. Proc Natl Acad Sci U S A. 1995. PMID: 7777575 Free PMC article.
-
Loss of drug-stimulated topoisomerase II DNA breaks in living cells is different at two unrelated loci.Nucleic Acids Res. 2000 Sep 1;28(17):3289-93. doi: 10.1093/nar/28.17.3289. Nucleic Acids Res. 2000. PMID: 10954596 Free PMC article.
-
Different topoisomerase II antitumor drugs direct similar specific long-range fragmentation of an amplified c-MYC gene locus in living cells and in high-salt-extracted nuclei.Proc Natl Acad Sci U S A. 1995 Jan 3;92(1):102-6. doi: 10.1073/pnas.92.1.102. Proc Natl Acad Sci U S A. 1995. PMID: 7816796 Free PMC article.
-
Role of minor groove width and hydration pattern on amsacrine interaction with DNA.PLoS One. 2013 Jul 29;8(7):e69933. doi: 10.1371/journal.pone.0069933. Print 2013. PLoS One. 2013. PMID: 23922861 Free PMC article.